CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 65 enrolled
Drug / intervention
Dalteparindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00525057
NCT00525057N/ACompleted
CompareCT.gov

DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study

M.D. Anderson Cancer Center·interventional·Posted Sep 5, 2007·Updated Jan 22, 2021

In Brief

A clinical study evaluating Dalteparin for Bone Sarcoma and 6 related conditions. Completed, enrolled 65 participants across 1 site.

Detailed Summary

This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm, Pathologic Fracture, Plasma Cell Myeloma, Soft Tissue Sarcoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 5, 2007
Enrollment StartJul 7, 2006
Primary CompletionJun 19, 2020
TodayJul 2, 2026
Enrollment to primary: 14.0 yearsPosted 18.8 years ago

Interventions

Dalteparindrug

Given SC